Alembic Pharma

Alembic Pharmaceuticals has received regulatory clearance from the U.S. Food and Drug Administration for a generic anti-fungal medication, strengthening its presence in the highly competitive U.S. generics market. The approval enables the company to commercialize the product in one of its most important export geographies, supporting revenue diversification and scale. Industry analysts view the development as a validation of Alembic’s compliance capabilities and manufacturing standards, particularly at a time when regulatory scrutiny remains intense.

Alembic Pharmaceuticals has received a crucial clearance from the United States Food and Drug Administration (USFDA) for its latest ophthalmic formulation, marking another milestone in the company’s regulatory track record. The approval strengthens Alembic’s presence in the lucrative U.S. generics market and expands its portfolio in specialized treatments, particularly within the eye-care segment. As global demand for affordable ophthalmic therapies continues to rise, the approval positions the company for strategic growth.

Alembic Pharmaceuticals Ltd. has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dasatinib Tablets in multiple strengths. This marks a significant milestone for the Indian drugmaker, granting it entry into the U.S. market for a high-value oncology medicine used in the treatment of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). The approval reinforces Alembic’s growing presence in complex generics and regulated markets, with the U.S.